Hainan Haili Pharmaceutical Co., Ltd.
-
Founded in:
1992-12-30 -
Country:
China -
Address:
No. 9 Haili Road, Yonggui Industrial Development Zone, Xiuying District, Haikou City -
Tax NO.:
9146000020133914XP -
Registered Funds:
60 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| BAPHICACANTHIS CUSIAE RHIZOMA ET RADIX |
Not yet clear
More
Not yet clear |
0 | ||
| ISATIDIS FOLIUM |
Not yet clear
More
Not yet clear |
0 | ||
| HERBA BIDENTIS |
Not yet clear
More
Not yet clear |
0 | ||
| Gangmei |
Not yet clear
More
Not yet clear |
0 | ||
| mountain sesame |
Not yet clear
More
Not yet clear |
0 | ||
| Acetaminophen |
Not yet clear
More
Not yet clear |
103-90-2 | 68 | |
| Andrographis leaf superfine powder |
Not yet clear
More
Not yet clear |
0 | ||
| Moroxydine hydrochloride |
Not yet clear
More
Not yet clear |
3160-91-6 | 12 | |
| Chlorphenamine maleate |
Not yet clear
More
Not yet clear |
113-92-8 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Roxithromycin |
This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.
More
This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. |
80214-83-1 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Glibenclamide |
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect
More
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect |
1.25mg | 10238-21-8 | 28 |
| 1，1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization
More
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization |
250mg | 15537-72-1 | 55 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Glibenclamide |
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect
More
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect |
1.25mg | 10238-21-8 | 28 |
| 1，1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization
More
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization |
250mg | 15537-72-1 | 55 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ribavirin |
This product is a broad-spectrum antiviral drug. Its mechanism of action is mainly to inhibit inosine dehydrogenase, block the conversion of inosine-phosphate to xanthine-phosphate, thereby inhibiting nucleic acid synthesis and preventing viral replication.
More
This product is a broad-spectrum antiviral drug. Its mechanism of action is mainly to inhibit inosine dehydrogenase, block the conversion of inosine-phosphate to xanthine-phosphate, thereby inhibiting nucleic acid synthesis and preventing viral replication. |
36791-04-5 | 33 |